Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Generics [UK] Ltd t/a Mylan, Station Close, Potters Bar, Herts. EN6 lTL
Flutamide 250 mg Tablets.
| Pharmaceutical Form |
|---|
|
Tablets. Yellow biconvex tablets marked ‘FT’ score ‘250’ on one side with a ‘G’ on the reverse. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. |
Each tablet contains 250 mg of flutamide.
Excipient of known effect: Each tablet contains 221.7 mg of lactose monohydrate.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Flutamide |
Flutamide is a non-steroidal, highly specific, orally active anti-androgenic agent. The pharmacologically active metabolite, hydroxyflutamide, is believed to exert an anti-androgenic effect directly on the target tissues, either by inhibiting androgen uptake or by blocking cytoplasmic and nuclear binding of androgen. Flutamide is indicated for the treatment of advanced prostatic carcinoma in which suppression of testosterone effects is indicated. |
| List of Excipients |
|---|
|
Cellulose, microcrystalline |
Flutamide tablets are packaged either in PVC/aluminium blister packs or in polypropylene pots with polyethylene caps (with optional polyethylene ullage filler), containing 20, 21, 30 50, 60, 84, 100, 105, 250 or 10*21 tablets.
Not all pack sizes may be marketed.
Generics [UK] Ltd t/a Mylan, Station Close, Potters Bar, Herts. EN6 lTL
PL 04569/0338
22 December 1997 / December 2002
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
